Klinefelter syndrome is a rare condition in which one or more extra X chromosomes are present in a male. About 60% of the embryos with Klinefelter’s syndrome do not survive the fetal period. Mosaic Klinefelter syndrome occurs when some of the cells in the body have an extra X chromosome. These males can have the same or milder symptoms. Klinefelter syndrome is not considered an inherited condition. The risk of Klinefelter syndrome reoccurring in another pregnancy is not increased about the general population risk.
According to the researchers of national human research institutes, the Klinefelter syndrome condition cannot be diagnosed easily, due to its unidentifiable symptoms and signs among males. The signs of this condition are different and also gets overlap with symptoms of other health disorders. Due to this, various healthcare organizations such as the NIH and FDA are increasing their awareness regarding this health disorder, by stressing the parents to conduct all kinds of health check-ups to identify this disease. This syndrome can be prevented if detected at early stage and also can be prevented from development. Moreover, the awareness among the population reading this syndrome is also increasing. In February 2016, Lupin Pharmaceuticals, Inc. launched a testosterone topical solution in the U.S. for males, who are suffering from hormone deficiencies.
However certain factors that can hamper the growth of this market in near future are adverse side effect of the drugs, shortage of treatment facilities and alternative treatment plans.
The global Klinefelter Syndrome Treatment Market is dominated by many market players. The key players in the market are engaged in new launches of drug and devices so as to maintain the strategic collaborations to hold its market position.
Some of the key players in the Global klinefelter syndrome treatment market are is Allergan plc, AbbVie, Inc., Endo Pharmaceuticals, Inc., Kyowa Kirin International plc, Eli Lilly and Company, Mylan N.V., Lupin Pharmaceuticals, Pfizer, Inc.
Request For Free Sample Copy :https://www.marketresearchfuture.com/sample_request/6766
North America dominates the market share for klinefelter syndrome treatment market and the reason being many market players are engaged in development of new drug product innovation, high presence of treatment centres for this disorder and increasing awareness among people. Approximately 3000 affected boys are born each year in the United Sates with this syndrome and about 3% of the infertile male population have Klinefelter syndrome.
Europe is expected to be the second largest market in the globe owing to the increasing aging population, increasing prevalence of this syndrome and increasing research base. Whereas rise in susceptible immune compromised patient population is responsible for market growth in this region. According to Europe PMC report the prevalence rate of KS in males in 2017 with breast cancer was found to be 7.5 per cent, a much higher rate than previously reported (approximately 3 per cent)
Asia-Pacific is anticipated to be the fastest growing market owing to the changing lifestyle, increase in population, increasing awareness among people regarding this disorder and increasing healthcare expenditure by government are some of the factor responsible for market growth in this region.
Middle East and Africa is expected to account for the smallest share in the Global klinefelter syndrome treatment market due to underdeveloped healthcare sector, lack of technical knowledge, and poor medical facilities.
Browse Complete Report Details @ https://www.marketresearchfuture.com/reports/klinefelter-syndrome-treatment-market-6766
Global klinefelter syndrome treatment market is segmented into treatment and end-users. Based on treatment type the market is further segmented into testosterone replacement therapy,
fertility treatment breast tissue removal and others. Fertility treatment is further sub-segmented into surgeries and hormone treatments and others
On basis of end-user market is further segmented into hospital and clinics, ambulatory surgeries, medical research centres, academic institutes others.